Meeting
2011 ASCO Annual Meeting
Evaluation of the JAK2 V617F mutational status in coronary patients.
Authors
K. Gasser
Academic Teaching Hospital Feldkirch, Feldkirch, Austria
K. Gasser , A. Muendlein , N. Stark , T. Winder , P. Rein , C. H. Saely , K. Geiger , S. Geller-Rhomberg , B. L. Hartmann , B. Kohler , H. Drexel , A. Lang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6585)
Abstract #
6585
Poster Bd #
36F
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Preclinical evaluation of JAK2 specific investigational oligonucleotide for the treatment of MDS/PV.
First Author: Bartlomiej Przychodzen
Poster
2023 ASCO Annual Meeting
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
First Author: Lucia Masarova
Poster
2023 ASCO Annual Meeting
Association of Agent Orange and myeloproliferative neoplasms, thrombosis, and bleeding among veterans.
First Author: Andrew Chua Tiu
Poster
2014 ASCO Annual Meeting
RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).
First Author: Francesco Passamonti